Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Gastroenterol Hepatol. 2013 Jun;11(6):612-9.e1. doi: 10.1016/j.cgh.2013.04.003. Epub 2013 Apr 11.

Emerging therapeutic targets for hepatitis C virus infection.

Author information

  • 1Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, USA.

Erratum in

  • Clin Gastroenterol Hepatol. 2013 Aug;11(8):1040.

Abstract

Therapy for hepatitis C virus (HCV) is a rapidly evolving field wherein traditional treatment with the nonspecific antiviral agents pegylated interferon (IFN)-alfa and ribavirin has been and will continue to be supplanted by combinations of targeted therapies against HCV with and without concomitant pegylated IFN and/or ribavirin, resulting in markedly superior rates of viral clearance. Exhaustive study of HCV structure and replication through the development of in vitro systems has enabled the development of numerous novel direct acting antiviral agents that currently are undergoing clinical trials. As our understanding of the HCV virus and its antiviral targets increases, the future of HCV therapy holds the promise of high rates of viral eradication in all patient populations, many or all of whom will be treatable with IFN-free combinations of all-oral agents.

Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk